Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Accumulated Expenses (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Accumulated Expenses for 11 consecutive years, with $49.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Accumulated Expenses fell 9.92% to $49.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $49.9 million, a 9.92% decrease, with the full-year FY2025 number at $49.9 million, down 9.92% from a year prior.
  • Accumulated Expenses was $49.9 million for Q4 2025 at Intellia Therapeutics, up from $16.8 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $67.0 million in Q4 2023 to a low of $6.2 million in Q1 2021.
  • A 5-year average of $30.0 million and a median of $21.4 million in 2022 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: surged 301.99% in 2023, then tumbled 77.25% in 2025.
  • Intellia Therapeutics' Accumulated Expenses stood at $20.4 million in 2021, then increased by 6.97% to $21.8 million in 2022, then surged by 207.73% to $67.0 million in 2023, then fell by 17.4% to $55.4 million in 2024, then dropped by 9.92% to $49.9 million in 2025.
  • Per Business Quant, the three most recent readings for NTLA's Accumulated Expenses are $49.9 million (Q4 2025), $16.8 million (Q3 2025), and $41.6 million (Q2 2025).